Contact us to get started

Hope begins here.

If you're an HR or benefits professional seeking cancer resources for your employees, or a consultant looking to provide best-in-class cancer support for your clients, share a few details below. We’ll reach out to help your company get started.

If you’re an employee looking for your AccessHope benefit, call 800.423.3232 and select Option 1.

January 12, 2024

AccessHope 2023 Year-in-Review

In For Employers, For Consultants

See All Blog Posts >

AccessHope is a revolutionary cancer benefit for members, their families, and caregivers who are facing cancer in their lives. Through our network of National Cancer Institute-Designated Comprehensive Cancer Centers, we remotely deploy the latest evidence-based recommendations, research, knowledge, and insights to members and their treating oncologists across the country — no matter where they live.


What we saw and heard

The most common cancers our experts reviewed in 2023 were hematologic/lymphoid, gastrointestinal, and breast.
Our Cancer Support Team (CST) provides information to members, their families, and their caregivers. Compassionate, specialized, and experienced oncology nurses responded to questions that covered a range of topics in 2023 and these were among the most common:

  • Helping members understand diagnoses
  • Providing information on how to manage side effects, ongoing care and emotional well-being
  • Preparing for doctor’s visits
  • Recommending a second opinion, when appropriate
  • Sharing information about clinical trials

AccessHope’s experts share innovations in cancer treatments

AccessHope’s network of subspecialist experts are at the forefront of the evolving landscape of cancer treatment, sharing the latest breakthroughs and medical innovations directly with treating oncologists for the benefit of their patients. Our AccessHope physicians highlight key developments that significantly impacted patient care in 2023:

  • Artificial intelligence is transforming cancer detection, particularly in colorectal cancer. SKOUT, a computer-aided detection tool, enhances the accuracy of polyp detection during colonoscopies.1 This innovation plays a crucial role in early intervention and contributes to the reduction of colorectal cancer incidence.

  • Major strides in the treatment of multiple myeloma. The 2023 FDA approval of talquetamab (Talvey)2 may bring new hope to individuals with multiple myeloma, offering a novel bispecific therapy targeting GPRC5D for those who have exhausted other treatment options. This advance is part of a surge in effective BCMA-targeted therapies that are delivering lasting and significant responses. Talvey is moving this type of therapy into earlier stages of treatment to potentially transform the disease's trajectory.

  • Antibody-drug conjugates (ADCs) establish their place in cancer treatment. With a novel mechanism-of-action that delivers a toxic ‘payload’ into cancer cells via an antibody, ADCs are showing tremendous promise. In breast cancer, the ADC sacituzumab govitecan (Trodelvy) was confirmed to improve disease control and survival over standard chemotherapy in individuals with a certain type of advanced breast cancer,3 and another ADC, mirvetuximab soravtansine (Elahere), was recently approved for the treatment of a particular subtype of advanced ovarian cancer.4,5 Other ADCs, like trastuzumab deruxtecan (already approved in certain types of breast, lung, and stomach cancer as the prescription medicine Enhertu), are being actively studied in clinical trials to see whether they can improve upon the current standards of care in other types of cancer.6

  • Precision medicine takes a stride forward in colorectal cancer as a randomized trial establishes the efficacy of targeting a specific gene mutation. While the drug sotorasib was shown to be effective in lung cancers that harbor this mutation, it proved ineffective in colorectal cancer. However, a new study combining sotorasib with an existing agent showed success in heavily pretreated patients with colorectal cancer, marking a significant breakthrough in targeted therapy for this population.7,8 This opens the door to new discoveries targeting other alterations in the same gene, which is found in about 50% of patients with colorectal cancer.

  • First new drug in colorectal cancer in 8 years. The recent FDA approval of fruquintinib,9 a tyrosine kinase inhibitor (TKI), signifies a notable step in colorectal cancer, which had lagged behind other cancers in new drug approvals. Fruquintinib's approval represents a significant addition to available agents, providing hope and broadening treatment options for a large population of colorectal cancer patients.

Expanding our reach through new partnerships

In September 2023, Johns Hopkins Medicine joined our other five National Cancer Institute-Designated Comprehensive Cancer Centers in the AccessHope’s network. We are changing the way leading-edge cancer expertise is delivered and continually finding ways to extend our reach to our clients and members. Check out for more information. Be sure to subscribe to our newsletter and receive updates!

 Iterative Health Announces Upcoming U.S. Availability of SKOUT®: Real-Time AI for Polyp Detection. Business Wire. Published May 4, 2023. Accessed December 14, 2023.
2 FDA D.I.S.C.O. Burst Edition: FDA approvals of Talvey (talquetamab-tgvs) for relapsed or refractory multiple myeloma, and Elrexfio (elranatamab-bcmm) for relapsed or refractory multiple myeloma. U.S. Food & Drug Administration. Updated September 26, 2023.,an%20anti%2DCD38%20monoclonal%20antibody. Accessed December 14 2023. 
3 Tolaney SM, Bardia A, Marmé F, et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). J Clin Oncol 2023 41:16_suppl, 1003. Doi: 10.1200/JCO.2023.41.16_suppl.1003. Accessed December 14, 2023.
4 Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. J Clin Oncol. 2023;41(13):2436-2445. doi:10.1200/JCO.22.01900. Accessed December 14, 2023.
5 Moore KN, Angelergues A, Konecny GE, et al.; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. Accessed December 14, 2023.
6 Funda Meric-Bernstam, Vicky Makker, Ana Oaknin, et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. J Clin Oncol 2023;41(7)_suppl: LBA3000. Doi: 10.1200/JCO.2023.41.17_suppl.LBA3000 Journal of Clinical Oncology 41, no. 17_suppl (June 10, 2023) LBA3000-LBA3000. Accessed December 14, 2023.
7 Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med 2023;389:2125-39.
8 Moore, Vicki. Sotorasib Plus Panitumumab Dubbed New Standard Care for Metastatic Colorectal Cancer. Cancer Therapy Advisor. Published October 22, 2023. Accessed December 14, 2023. 

9 FDA approves fruquintinib in refractory metastatic colorectal cancer. U.S. Food & Drug Administration. Updated November 8, 2023. Accessed December 14, 2023.




UT Southwestern Medical Center Partners with AccessHope to extend nationwide access to cancer expertise 

Read the Press Release